Table 1.
Clinical and demographic characteristics.
| Description | HIV-1-negative (n = 41) | HIV-1-positive (n = 47) | p-value1 |
|---|---|---|---|
| Age (years): median (IQR2) | 45 (19–73) | 46 (18–75) | 0.934 |
| Gender: female number (%) | 34 (82.93%) | 37 (78.72%) | >0.99 |
| CD4+ T-cell count (cells/μL): median (IQR2) | ND3 | 434 (31–1,384) | ND3 |
| ART duration (months): median (IQR2) n = 37 | ND3 | 54 (6–142) | ND3 |
| Viral load (copies/mL): median (IQR2) n = 38 | ND3 | 3,729 (20–200,936) | ND3 |
| sCD14 (μg/mL): mean ± SD | 0.503 ± 0.443 | 0.794 ± 0.791 | 0.238 |
| IFABP (ng/mL): mean ± SD | 0.987 ± 0.557 | 1.409 ± 0.898 | 0.042 |
| LBP (μg/mL): mean ± SD | 4.754 ± 2.14 | 5.096 ± 2.153 | 0.252 |
1
Statistical comparison between seronegative controls and HIV-1 infected individuals was performed by Wilcoxon rank sum test or Fisher’s exact test for gender.
2
Interquartile range.
3
Not determined.
RT, antiretroviral therapy; sCD14, soluble CD14; IFABP, intestinal free acid binding protein; LBP, lipoprotein binding protein.